Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs (Q39005594)

8 September 2017

Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs (English)

1 reference

8 September 2017

1 reference

Leishmania donovani

1 reference

10

1 reference

Daniella Castanheira Bartholomeu

8 September 2017

7

Daniella Castanheira Bartholomeu

0 references

Rodrigo Corrêa-Oliveira

8

Rodrigo Correa-Oliveira

1 reference

8 September 2017

6

Lilian Lacerda Bueno

1 reference

8 September 2017

Natasha Delaqua Ricci

5

Natasha Delaqua Ricci

1 reference

8 September 2017

Jacqueline Araújo Fiuza

1

Jacqueline Araújo Fiuza

1 reference

8 September 2017

4

Sreenivas Gannavaram

1 reference

8 September 2017

Angamuthu Selvapandiyan

3

Angamuthu Selvapandiyan

1 reference

8 September 2017

Helton da Costa Santiago

2

Helton da Costa Santiago

1 reference

8 September 2017

Hira Lal Nakhasi

9

1 reference

8 September 2017

language of work or name

English

0 references

publication date

8 February 2013

1 reference

8 September 2017

1 reference

8 September 2017

31

1 reference

8 September 2017

14

1 reference

8 September 2017

1785-1792

1 reference

Leishmaniasis: current situation and new perspectives

8 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

The leishmaniases as emerging and reemerging zoonoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Autochthonous visceral leishmaniasis in dogs in North America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Canine leishmaniosis in the United Kingdom: a zoonotic disease waiting for a vector?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

inferred from DOI database lookup

7 January 2021

based on heuristic

Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

A long-lasting topical deltamethrin treatment to protect dogs against visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

The current status of zoonotic leishmaniases and approaches to disease control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Chemotherapy of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Live attenuated Leishmania vaccines: a potential strategic alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Profile of central and effector memory T cells in the progression of chronic human chagas disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

In vitro cultured peripheral blood mononuclear cells from patients with chronic schistosomiasis mansoni show immunomodulation of cyclin D1,2,3 in the presence of soluble egg antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

T-cell response in human leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

T-cell and cytokine responses in leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

CD8(+) T cells in leishmania infections: friends or foes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Second-generation vaccines against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

T helper (h)1/Th2 and Leishmania: paradox rather than paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Leishmania vaccines: progress and problems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.048

10.1016/J.VACCINE.2013.01.048

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference